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Abstrak 
 
Pengenalan: Osteoartritis (OA) atau keradangan sendi merupakan penyakit sendi yang kerap 
berlaku di kalangan warga tua, rawatannya sering melibatkan pengambilan ubat tahan sakit, 
namun ini boleh menyebabkan kesan sampingan yang tidak diingini. Secara tradisional, 
pengambilan Momordica charantia (MC) atau peria dipercayai dapat membantu dalam 
mengurangkan sakit berkaitan keradangan termasuk keradangan sendi.  
 
Objektif: Mengenal pasti keberkesanan suplemen peria dalam mengurangkan kesakitan 
untuk penyakit keradangan sendi lutut.  
 
Metodologi: Ini adalah sebuah kajian yang melibatkan tujuh puluh lima pesakit 
osteoarthritis, yang dibahagi kepada dua kumpulan (tiga puluh lapan dalam kumpulan peria 
dan tiga puluh tujuh dalam kumpulan placebo). Semua peserta telah mengambil suplemen 
peria atau placebo harian untuk tempoh tiga bulan. Peserta dibenarkan mengambil ubat tahan 
sakit sekiranya diperlukan, dan pengambilan ubat ini telah direkodkan. Tahap kesakitan 
dinilai setiap bulan dengan menggunakan “Knee Injury and Osteoarthritis Outcome Score” 
(KOOS) dan EQ-5D-3L (EuroQol- 5 Dimensions- 3 Levels) Health Questionnaire. 
Perbandingan dan analisis antara dua kumpulan dibuat untuk menentukan perubahan dalam 
markah KOOS, EQ-5D-3L dan pengambilan ubat tahan sakit sebelum dan selepas 
pengambilan suplemen, menggunakan ‘repeated measures ANOVA’. 
 
Keputusan: Selepas pengambilan suplemen selama tiga bulan, markah KOOS dan EQ-5D-
3L telah menunjukkan peningkatan, dan pengambilan ubat tahan sakit dikurangkan. Berat 
badan, BMI dan tahap gula berpuasa telah berkurang dalam peserta kumpulan MC. 
vi 
 
Kumpulan placebo turut menunjukkan peningkatan dalam subset tertentu KOOS dan EQ-5D-
3L, tetapi pengambilan ubat tahan sakit telah bertambah. 
 
Kesimpulan:  Suplemen Momordica charantia merupakan alternatif yang berkesan untuk 
mengurangkan kesakitan penyakit osteoarthritis, serta mengurangkan pengambilan ubat tahan 
sakit. Manfaatnya dapat dikesan seawal tiga bulan. 
 
Kata kunci: Ubat tahan sakit, peria, momordica charantia, keradangan lutut  
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Abstract 
 
Introduction: Osteoarthritis (OA) is a common problem affecting the joints in the elderly, 
and its conservative treatment includes the usage of analgesia, which frequently leads to 
undesirable side effects. Traditionally, Momordica charantia (MC) or bitter melon is believed 
to be effective in relieving pain, including that caused by knee osteoarthritis.   
 
Objective: To determine the effects of MC in reducing pain among primary knee 
osteoarthritis (OA) patients.  
 
Methodology: This study involves 75 patients with primary knee osteoarthritis, who were 
divided into two groups (thirty-eight patients in the MC group and thirty-seven in the placebo 
group). The patients underwent 3 months daily supplementation of either MC or placebo. 
Rescue analgesia was allowed as needed, and rescue analgesia intake was recorded. Pain and 
symptoms during supplementation period were assessed monthly using Knee Injury and 
Osteoarthritis Outcome Score (KOOS) and EQ-5D-3L (EuroQol- 5 Dimensions- 3 Levels) 
Health questionnaire. Comparison and analysis between the two groups were done using 
“repeated measures ANOVA” to determine the changes in KOOS, EQ-5D-3L and analgesic 
scores after supplementation. 
 
Results: After 3 months supplementation period, there were significant improvements in 
KOOS subscale and EQ-5D-3L score with a reduction in analgesic score. Body weight, BMI 
and FBS reduced significantly in the MC group. The placebo group had also shown 
significant improvements in certain KOOS subscale and EQ-5D-3L dimension score, but 
with increased of analgesic score.  
viii 
 
Conclusion: Momordica charantia supplementation offers a safe alternative in reducing pain 
among the primary knee OA patients, while reducing the need for analgesia consumption. 
These beneficial effects can be seen as early as 3 months of supplementation. 
 
Key words: Analgesic, bitter melon, momordica charantia, osteoarthritis  
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INTRODUCTION 
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1.1 INTRODUCTION 
 
Osteoarthritis (OA) is the major cause of chronic disability at older ages, notably when the 
knee and hip joints are involved. The prevalence of knee OA increases rapidly with 
advancing age. It has been estimated that, with regards the incidence of knee OA among 
persons between 60 to 79 years of age in western European countries, there will be an 
increase from 18% to 25% and from 24% to 40% in men and women respectively1. In 
Malaysia, the prevalence of knee OA among the population aged more than 65 years old is 
estimated to be at 30%. In addition, about 9.3% of Malaysian adults have experienced knee 
pain, and there was a trend that showed a rise in pain rate, whereby it had increased to 23% 
for population aged more than 55 years old, and to 39% in population more than 65 years 
old2. Indeed, as the world population is expected to live longer, the prevalence of OA is also 
being predicted to increase and affect more people around the globe. 
 
Knee OA patients seek treatment for joint pain and daily life activity limitations. OA is one 
of the major health problems in which patients prefer to use alternative methods of 
treatment3, particularly after experiencing side effects of painkillers; or failure of 
conventional medication to improve the symptoms. Alternative treatments that are used for 
OA include herbs, supplements, acupuncture, and electromagnets. Traditional or herbal 
medicine has long been a viable treatment option for a large majority of people in this region. 
Globally, the use of traditional/herbal medicine has been garnering growing attention as it 
offers better accessability and affordability in the face of rising cost of health care services4.  
 
Momordica charantia (MC), a type of tropical plant of the Cucurbitaceae family, is widely 
planted in Asia, East Africa and South America. Famously recognised for its bitter taste, it is 
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commonly used in cooking and traditional medicine. MC is locally referred to as bitter 
melon, karela, balsam pear or bitter gourd5, 6. 
  
Previous studies have reported the healing properties of MC such as antidiabetic, 
antioxidative, antiviral, anti-inflammatory, cholesterol-lowering effects, as well as treatment 
of infections6,7,8,9. Most studies done on the effects of MC pertain to diabetes mellitus in 
humans. There were also studies performed among adult subjects where metabolic syndrome 
incidence rate was decreased with MC supplementation10. 
 
Several animal studies have demonstrated the analgesic response of MC11, 12, 13, including one 
conducted by Patel and Ullah et al, which revealed that ethanolic MC extract had 
significantly reduced acetic acid-induced writhing as well as offered significant protection in 
tail-immersion test in mice12, 13. Acetic acid-induced writhing method is an effective approach 
to assess analgesics that are peripherally active; agents that successfully decrease the writhing 
count most possibly demonstrated its analgesic activity via peripheral mechanism by 
inhibition of prostaglandin synthesis. The pain reduction of MC extract may be led by its 
activity in inhibiting the production of prostaglandin12,13, which is involved in causing 
inflammatory pain in knee OA.  None of such studies have been carried out in the human 
population. Therefore, this study is done to assess the analgesic effect of MC supplement 
among primary knee OA patients. 
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2.1. General Objective 
1. To determine the efficacy of MC supplement in pain reduction among primary knee 
OA patients.  
 
2.2. Specific Objectives 
1.  To determine the effectiveness of MC supplement in pain reduction, improvement of   
symptoms and in carrying out activities of daily living, sports/recreational activities, and 
quality of life by measuring Knee injury and Osteoarthritis Outcome Score (KOOS). 
 
2. To determine the efficacy of MC supplement in improving the quality of life among 
OA patients using the EQ-5D questionnaire. 
 
3. To determine the change of frequency of analgesia intake with MC supplementation. 
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3.2 ABSTRACT 
 
Introduction: Osteoarthritis (OA) is a common problem affecting the joints in the elderly, 
and its conservative treatment includes the usage of analgesia, which frequently leads to 
undesirable side effects. Traditionally, Momordica charantia (MC) or bitter melon is believed 
to be effective in relieving pain, including that caused by knee osteoarthritis.   
 
Objective: To determine the effects of MC in reducing pain among primary knee 
osteoarthritis (OA) patients.  
 
Methodology: This study involves 75 patients with primary knee osteoarthritis, who were 
divided into two groups (thirty-eight patients in the MC group and thirty-seven in the placebo 
group). The patients underwent 3 months daily supplementation of either MC or placebo. 
Rescue analgesia was allowed as needed, and rescue analgesia intake was recorded. Pain and 
symptoms during supplementation period were assessed monthly using Knee Injury and 
Osteoarthritis Outcome Score (KOOS) and EQ-5D-3L (EuroQol- 5 Dimensions- 3 Levels) 
Health questionnaire. Comparison and analysis between the two groups were done using 
“repeated measures ANOVA” to determine the changes in KOOS, EQ-5D-3L and analgesic 
scores after supplementation. 
 
Results: After 3 months supplementation period, there were significant improvements in 
KOOS subscale and EQ-5D-3L score with a reduction in analgesic score. Body weight, BMI 
and FBS reduced significantly in the MC group. The placebo group had also shown 
significant improvements in certain KOOS subscale and EQ-5D-3L dimension score, but 
with increased of analgesic score.  
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Conclusion: Momordica charantia supplementation offers a safe alternative in reducing pain 
among the primary knee OA patients, while reducing the need for analgesia consumption. 
These beneficial effects can be seen as early as 3 months of supplementation. 
 
Key words: Analgesic, bitter melon, momordica charantia, osteoarthritis  
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3.3 INTRODUCTION 
 
Osteoarthritis (OA) is the major cause of chronic disability at older ages, notably when the 
knee and hip joints are involved. The prevalence of knee OA increases rapidly with 
advancing age. In the European Union only, there are approximately 100 million people who 
are suffering from knee OA. In fact, it has been estimated that, with regards the incidence of 
knee OA among persons between 60 to 79 years of age in western European countries, there 
will be an increase from 18% to 25% and from 24% to 40% in men and women respectively1. 
In Malaysia, the prevalence of knee OA among the population aged more than 65 years old is 
estimated to be at 30%. In addition, about 9.3% of Malaysian adults have experienced knee 
pain, and there was a trend that showed a rise in pain rate, whereby it had increased to 23% 
for population aged more than 55 years old, and to 39% in population more than 65 years 
old2. Indeed, as the world population is expected to live longer, the prevalence of OA is also 
being predicted to increase and affect more people around the globe. 
 
Knee OA patients seek treatment for joint pain and daily life activity limitations, especially 
walking, kneeling or squatting, and climbing upstairs. The main goal of treatment is 
improvement of function and quality of life. OA is one of the major health problems in which 
patients prefer to use alternative methods of treatment3, particularly after experiencing side 
effects of painkillers; or failure of conventional medication to improve the symptoms. 
Alternative treatments that are used for OA include herbs, supplements, acupuncture, and 
electromagnets. Owing to cultural traditions or lack of choices, traditional or herbal medicine 
has long been a viable treatment option for a large majority of people in this region. Globally, 
the use of traditional/herbal medicine has been garnering growing attention as it offers better 
accessability and affordability in the face of rising cost of health care services4.  
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Momordica charantia (MC), a type of tropical plant of the Cucurbitaceae family, is widely 
planted in Asia, East Africa and South America. Famously recognised for its bitter taste, it is 
commonly used in cooking and traditional medicine. MC is locally referred to as bitter 
melon, karela, balsam pear or bitter gourd5, 6. 
  
Previous studies have reported the healing properties of MC such as antidiabetic, 
antioxidative, antiviral, anti-inflammatory and cholesterol-lowering effects6. The phenolic 
compounds found in MC may have antioxidative and antimutagenic properties7, 8. In 
traditional practice, almost all parts of MC such as fruits, stems, leaves and roots are used in 
the treatment of various human diseases like hyperlipidaemia, digestive disorders, microbial 
infection and menstrual problems9. Most studies done on the effects of MC pertain to 
diabetes mellitus in humans. There were also studies performed among adult subjects where 
metabolic syndrome incidence rate was decreased with MC supplementation10.  
 
Several animal studies have demonstrated the analgesic response of MC11, 12, 13, including one 
conducted by Patel and Ullah et al, which revealed that ethanolic MC extract had 
significantly reduced acetic acid-induced writhing as well as offered significant protection in 
tail-immersion test in mice12, 13. Acetic acid-induced writhing method is an effective approach 
to assess analgesics that are peripherally active; agents that successfully decrease the writhing 
count most possibly demonstrated its analgesic activity via peripheral mechanism by 
inhibition of prostaglandin synthesis. The pain reduction of MC extract may be led by its 
activity in inhibiting the production of prostaglandin12,13, which is involved in causing 
inflammatory pain in knee OA.  None of such studies have been carried out in the human 
population. Therefore, this study is done to assess the analgesic effect of MC supplement 
among primary knee OA patients. 
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3.4 METHODOLOGY 
 
This is a single-blinded randomized controlled study. This study has been conducted in 
Hospital Universiti Sains Malaysia from October 2015 until October 2016. Study protocols 
had been approved by the Universiti Sains Malaysia (USM) Research Ethics Committee 
(Human) and was conducted according to the principles of the Declaration of Helsinki. All 
patients were required to sign an informed consent form before participation in the trial. Each 
patient was included in the trial for 3 months. 
 
Eighty primary knee osteoarthritis (OA) patients who attended our orthopaedic clinic and 
who fulfill the inclusion criteria were recruited. To be eligible, the patients had to be 
confirmed as primary unilateral or bilateral knee osteoarthritis patients with the diagnosis 
made according to the clinical and radiological criteria of the American College of 
Rheumatology14; and OA grade between I and III, determined based on knee radiograph with 
the Kellgren-Lawrence classification15. Patients with debilitating medical conditions such as 
severe hematologic disorders or renal and liver disease, patients having grade IV knee OA, 
secondary knee OA,  or who have been planned for surgical intervention were not included in 
this study. Using an online randomization list generator, the patients were randomized 1:1 
into 2 groups: MC or placebo, with 40 patients in each arm. Patients had no knowledge of 
which arm of the trial they were allocated to. 
 
Commercially available MC capsules were obtained from a local manufacturer (CCM 
Duopharma Sdn Bhd). Similar-looking capsules of placebo containing inactive excipients 
were also prepared accordingly by a local manufacturer (Skinfix Technologies Sdn Bhd). 
Both manufacturers are GMP-certified (Good Manufacturing Practice-certified), and except 
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for supplying MC and placebo capsules, they were not involved in any part of this study. 
Both manufacturers also did not make any therapeutic claims of their products based on the 
findings of this study. The MC capsules are products registered with the National 
Pharmaceutical Regulatory Agency of the Malaysian Health Ministry. Both the MC and 
placebo were 500mg/capsule, with 60 capsules in each unlabeled identical bottle. The patient 
had no way of determining whether they were on MC supplement or placebo.  
 
Three capsules of MC or placebo were taken thrice daily post-meal for a 3-month 
supplementation period, resulting in a total of 4500mg consumption of MC supplementation 
or placebo per day. Current medications were continued as usual, patients were allowed to 
take rescue analgesia as required; but consumption of analgesia was to be recorded in an 
analgesia diary. Within supplementation period, all patients were asked to avoid intake of any 
MC-related foodstuff, corticosteroids and hyaluronic acid injections, and procedures such as 
arthroscopic surgery. Patients found to have violated the protocol was excluded. 
 
On the first visit, social demographic data, medical history, current medications and knee OA 
history were recorded for each participant. Baseline body weight, height and body mass index 
(BMI) were measured while blood was drawn for total cholesterol (TC), triglyceride (TG) 
and fasting blood sugar (FBS) measurements. The severity of knee pain and symptoms for 
each patient was quantified using the Knee Injury and Osteoarthritis Outcome Score (KOOS) 
and EQ-5D-3L Health questionnaires. Patients were then supplied with either MC or placebo 
capsules based on a randomization list and advised to follow the study procedure accordingly. 
During the second visit (one week after initiation), patients were assessed to evaluate 
compliance and safety of supplementation. Symptoms like nausea, vomiting, diarrhoea, 
discomfort or other side effects experienced by the patients after taking the trial medications 
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were recorded and further actions such as prescribing rescue analgesia were taken 
accordingly. For rescue analgesia, patients were prescribed tablet acetaminophen 1 gram stat 
for mild to moderate pain; and capsule celecoxib 200 milligram stat for severe pain (or tablet 
tramadol 50 milligram if unable to tolerate celecoxib). In addition, patients were provided 
with a medication diary to record the number and frquency of analgesia they had consumed. 
Change to other form of analgesia was not allowed except if they had informed the 
investigators beforehand. All patients were reassessed at first, second and third month of the 
supplementation period. Side effects of the supplementation and compliance were evaluated, 
and the medication diary collected. Compliance was measured based on the return of unused 
capsules by patients using this formula:  
 
Compliance = (no. of capsules taken/no. of capsules should have been taken) x 100 
 
Any patients taking less than 80% of capsules are considered non-compliant. Evaluation of 
pain, symptoms, quality of life and other related parameters was also performed using KOOS 
and EQ-5D-3L questionnaires while measurements of body weight, BMI, TC, TG and FBS 
were repeated after the 3-month supplementation period. 
 
Physical and biochemical measurements were performed at baseline and after the 3 months 
supplementation period. Weight and height were measured in standing position using a 
digital weighing scale with an attached measuring rod. BMI was calculated as weight in kg 
divided by height in m² (kg/m²). Fasting peripheral blood was withdrawn and sent to our 
laboratory for TC, TG and FBS measurements. KOOS is a widely used questionnaire in 
clinical trials to assess the patient’s pain, stiffness and physical function in relation to 
afflictions of the knee joints such as osteoarthritis. It has five subscales; Pain, Symptoms, 
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Function-Activities of Daily Living (ADL), Function-Sport and Recreation Activities 
(Sport/Rec), and knee-related Quality of Life (QOL). The previous week is the time frame 
considered each time the questionnaire is answered. For each item in the 5 subscales of the 
KOOS questionnaire, standardized answer options are given (5 Likert boxes) and each 
question was assigned a score from 0 to 4. A higher score for each subscale indicates better 
condition among patients16. 
 
The EQ-5D-3L questionnaire is a descriptive system that captures health-related quality of 
life. There are 2 parts in this validated questionnaire - the EQ-5D descriptive system and the 
EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises of 5 
dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort and Anxiety/Depression. 
Each dimension has 3 levels of severity: no problems, some problems and extreme problems;  
a lower score indicates less problems. The EQ VAS documents the patient’s self-rated health 
on a vertical, visual analogue scale. The scale has endpoints labelled ‘Best imaginable health 
state’ (highest) on one spectrum and ‘Worst imaginable health state’ (lowest) on the other. 
The EQ VAS is a quantitative measure of health outcome as perceived by the individual 
patients17. KOOS and EQ-5D-3L were measured at baseline and first, second and third 
months of the supplementation period. Analgesia intake was documented in the analgesia 
diary, including the type, date, and dosage of tablets taken. Score 1 was given for each tab 
acetaminophen 1 gram taken while score 2 was given for capsule celecoxib 200 milligram or 
tab tramadol 50 milligram. A lower score indicates less intake of analgesia. The analgesic 
score was recorded at each month of the supplementation period.  
 
Sample size calculation was done using Power and Sample Size Calculation software18. 
Power analysis (α = 0.05; Power = 0.8) determined that a sample size of 36 patients in each 
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arm was required for a detectable difference (δ) of 9.3 in total pain score using KOOS score 
between MC and placebo group. Based on the study by Giordano et al, the standard deviation 
(σ) was 13.919. Forty patients were enrolled per group to allow for 10% dropouts; therefore 
total sample size calculated was 80. 
 
The data was analyzed using Statistical Package for the Social Sciences (SPSS). All data 
were expressed as mean and standard deviation(SD). Within and between group changes for 
physical and biochemistry parameters were analysed using paired and independent t-test 
respectively. Changes of the analgesic score, KOOS and EQ-5D-3L in each and between the 
group throughout 3 months supplementation were analysed using repeated measures ANOVA 
(RMA). Significant change was indicated by p-value < 0.05.  
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3.5 RESULTS 
 
Of the eighty patients recruited, 2 patients from MC group and 3 patients from placebo group 
(all females) were withdrawn from the study, leaving 38 patients in MC group (15 males, 23 
females) and 37 patients in placebo group (9 males, 28 females) who had completed the 
study. Of the five drop-outs, three patients had mild allergic reaction (1 in MC group, 2 in 
placebo group) and two patients had defaulted follow-up (both 1 patient in each group) 
(Figure 1).  
 
Of the 75 participants who had completed the trial, 58.67% had Grade 2 OA (n=44), 33.33% 
Grade 3 OA (n=25) and 8% Grade 1 OA (n=6). There was no significant difference in age, 
OA grade and baseline value of body weight, BMI, TC and FBS between MC and placebo 
groups except for TG where placebo group showed higher TG. TG levels after the 
supplementation period in placebo group was also significantly higher compared to MC 
group. However, the mean values for baseline and post-TG were still within the 
recommended normal range (0.5-1.8 mmol/L). Interestingly, after a 3-month 
supplementation, body weight, BMI and FBS were reduced significantly in MC group when 
compared to the baseline, but no significant changes were seen in placebo group (Table 1). 
 
Throughout the 3-month MC supplementation, the analgesic score was significantly reduced 
and all subscales in KOOS questionnaire showed significant increase in its score. Except for 
the self-care dimension score, other dimensions score in EQ-5D-3L questionnaire were 
significantly decreased. Meanwhile, the EQ VAS score showed significant increase at the end 
of the supplementation period (Table 2).  
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Significant changes were also noted in the placebo group. However, in contrast to the MC 
group, the analgesic score in this group was increased. Scores in KOOS’ subscales namely 
pain, sport/rec and QOL were also increased. Similar to the MC group, scores of all 
dimensions in EQ-5D-3L questionnaire except self-care were reduced while EQ VAS was 
increased (Table 3).  
 
In addition, mean comparison between groups throughout the supplementation period only 
differ significantly in the analgesic score. It was also found that, there was a different trend in 
analgesic score between both groups where the MC group demonstrated a reduced trend 
whereas the placebo group showed an increased trend throughout the 3 months 
supplementation period (Figure 2). Also, no side effects were experienced by the 75 patients 
during supplementation period. . 
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3.6 DISCUSSION 
 
In the present study, baseline and post-TG were higher in placebo compared to the MC 
group, but still in normal range while post-body weight, BMI and FBS were reduced in MC 
group compared to the baseline. MC supplementation for 3 months offers significant 
improvement in pain management and quality of life among primary knee OA patients. Most 
importantly, these beneficial effects were achieved with the reduced consumption of 
analgesics. Surprisingly, patients receiving placebo had also shown significant improvement 
in their pain management and quality of life. However, this could partly be attributed to the 
increased intake of analgesia.  
 
In our study, MC supplementation did not show any adverse side effects. Only one patient 
claimed to have mild allergic reaction (nausea and giddiness) and was withdrawn from the 
study. An acute toxicity study in mice revealed that no toxic effects were seen with 
2000mg/kg oral administration of MC whereas further observation also recorded no mortality 
among the mice13. In their study, Patel et al had estimated LD50 for MC extract was more 
than 5000mg/kg12. Moreover, Tsai et al. used a dosage of 4.5-5.0g/day of MC as the 
supplementation dose in their study among adult Taiwanese and only two subjects were 
withdrawn due to dizziness and headache10.  
 
The reduction of body weight after MC consumption has been reported previously in animal 
studies20, 21, 22. In fact, MC supplementation has been reported to prevent and reduce adiposity 
caused by high fat diet in rats22, 23. The possible mechanism on how MC lowers the body 
weight and thus BMI, could lie in the increased lipolysis activity and this can be supported by 
the increased concentration of serum free fatty acid in studied animals23. Higher activity of 
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lipolysis may occur due to the need to sustain energy efficiency which is influenced by the 
hypoglycaemic effect of MC.  
 
Albeit the hypoglycaemic effect of MC has been in the centre of attention in discussing the 
medical potential of MC, majority of clinical studies involving MC hypoglycaemic effects 
have been performed with improper control, small sample size and suffered from poor 
methodologies without baseline characterisations24. Nevertheless, previous clinical trials and 
case studies have reported the reduction of blood glucose in diabetes patients after MC 
consumption25, 26, 27, 28, 29. The anti-diabetic effect of MC and its modes of action have been 
extensively reviewed previously6, 30. MC has been proposed to reduce blood glucose through 
various biochemical and physiological processes. These consist of increased glucose 
utilisation by skeletal muscle and peripheral cells, stimulation of pentose phosphate pathway 
key enzymes, stimulation of insulin secretion and glucose metabolism; with a concurrent 
inhibition in intestinal glucose uptake and hexokinase activity as well as suppression of some 
key gluconeogenic enzymes. Furthermore, MC also promotes preservation of pancreatic B 
cells and their functions6, 30. 
 
We found that with MC supplementation, our patients experienced less knee pain, symptoms 
and had reduced their intake of analgesia, while their daily activities and quality of life have 
improved. Our findings were in accordance with reports from previous animal studies where 
it was demonstrated that the methanol extract of MC seeds had manifested a significant 
analgesic response in rats and mice31. In addition, studies by Patel and Ullah et al revealed 
that ethanolic MC extract had significantly reduced acetic acid-induced writhing as well as 
offered significant protection in tail-immersion test in mice12, 13. Taken together, MC extracts 
had exhibited analgesic activity in animal models. Unfortunately, no studies had been carried 
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out in human subjects to explore the analgesic potential of MC, especially in pain-related 
diseases such as primary knee OA. Thus, the mechanism on how MC reduces pain in human 
remains unclear.  
 
However, based on previous animal studies by Patel and Ullah et al, the pain reduction of 
MC extract may be peripherally mediated, led by its activity in inhibiting prostaglandin 
synthesis12, 13. Acetic acid-induced writhing method is an effective approach to assess 
analgesics that are peripherally active; agents that successfully decrease the writhing count 
most possibly demonstrated its analgesic activity via peripheral mechanism by inhibition of 
prostaglandin synthesis32. In this method, localised inflammation response was triggered, 
resulting in increased levels of prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) in 
peritoneal fluid33. PGE2 is well known for its role in contributing to inflammatory pain34. 
Nonetheless, the consumption of ethanolic MC extract has reduced the writhing count 
significantly and it can be due to the inhibitory activity of MC extract on peripheral PGE2 
synthesis.. An increased level of PGE2 as well as cyclooxygenase-2 (COX-2) has been found 
in human OA tissue35. Furthermore, abundant data had suggested that PGE2 is often 
produced via COX-2 dependent pathway36 while COX-2 inhibition by dexamethasone, 
indomethacin or COX-2-selective inhibitor resulted in inhibition of PGE2 production in OA-
affected cartilage and also showed significant pain relief among knee OA patients37, 38.  
 
In the tail immersion method which was used to assess centrally acting analgesics39, higher 
reaction time in MC treated mice indicated that the analgesic activity of MC may also be 
centrally mediated. Four subtypes of PGE2 receptors, namely EP1, EP2, EP3 and EP4 may 
be present in sensory neurons and mediate the peripheral and/or spinal PGE2-induced 
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nociceptive process34, 40, but according to the report by Ullah in 2012, the involvement of 
prostaglandin may be minimised in this model13.  
 
Phytochemical examination of MC extract has found the presence of alkaloids, saponin, 
glycosides, steroids, sterol and phenolic compounds12, 13. Phenolic compound such as 
flavonoid has been found to effectively inhibit PGE2 production and COX-2 expression as 
well as down-regulated inducible microsomal prostaglandin E synthase-1 (mPGES-1) 
expression41. The antinociceptive activity of plant-isolated flavonoid as well as another 
phenolic compound, tannin, was also reported by other researchers previously42, 43. Therefore, 
the presence of these phytochemical compounds in MC might contribute to the pain reduction 
after consumption of MC.   
 
According to the study by Ullah et al, 500 mg/kg MC per oral in rats, edema induced by 
carrageenan was significantly reduced by 42.10 %13. Therefore, based on the formula by 
Reagan-Shaw et al, 2008 which is used to determine the human effective dose (HED) from 
animal study44, the HED for adult human with 60 kg body weight is 4.9g daily. For this study, 
the treatment group had consumed 3 capsules of MC thrice daily, giving a total dosage of 
4.5g daily. 
 
Surprisingly, the placebo group had also shown significant reduction in pain and symptom; 
with improved daily activity and quality of life. However, there was significant increase of 
analgesia intake throughout the study period. Mean analgesic score throughout study period 
in the placebo group was significantly different compared to the MC group which showed 
decreased intake of analgesia. Hence, it can be postulated that, improvement in pain, 
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symptom, daily activity as well as quality of life in the placebo group could be due to the 
increased intake of analgesia throughout study period. 
 
This study offers early understanding regarding the analgesic effects of MC, in particular 
among primary OA patients. Randomisation and blinding reduce bias among patients on 
supplementation they received. However, this study did not measure levels of pain-related 
cytokines such as COX-2 and PGE2 levels, thus the analgesic pathway of MC cannot be 
clearly delineated. Moreover, as the MC capsules used in this trial are made up of entire bitter 
melon fruits, the specific components that possess analgesic properties cannot be determined. 
In addition, the use of questionnaires to evaluate pain and symptoms of OA may be 
inaccurate and subjective. The intake of analgesia could be affected because some subjects 
have concurrent co-morbidities such as cervical spondylosis and spinal stenosis requiring 
painkillers. Pain relief by other alternatives such as physiotherapy or local ointments area also 
not accounted for.  
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3.7 CONCLUSION 
 
Our study has shed light on the potential analgesic effects of MC in humans. With MC 
supplementation, there was significant pain reduction, improvement of symptoms, daily 
activities and quality of life. In addition, it reduced the intake of analgesia and there were no 
major side effects reported. Therefore, it can be conceived that, Momordica charantia 
supplementation offers a safe alternative in reducing pain and improving symptoms among 
primary knee OA patients, while reducing the need for analgesia consumption. These 
beneficial effects can be seen as early as 3 months of supplementation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
